image
Healthcare - Biotechnology - NASDAQ - US
$ 11.64
14.2 %
$ 192 M
Market Cap
-0.59
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RAPT stock under the worst case scenario is HIDDEN Compared to the current market price of 11.6 USD, RAPT Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RAPT stock under the base case scenario is HIDDEN Compared to the current market price of 11.6 USD, RAPT Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RAPT stock under the best case scenario is HIDDEN Compared to the current market price of 11.6 USD, RAPT Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RAPT

image
$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
0 REVENUE
0.00%
-136 M OPERATING INCOME
-7.11%
-130 M NET INCOME
-11.19%
-83.3 M OPERATING CASH FLOW
14.17%
52.7 M INVESTING CASH FLOW
-49.39%
153 M FINANCING CASH FLOW
10463.37%
0 REVENUE
0.00%
-19.3 M OPERATING INCOME
64.63%
-17.2 M NET INCOME
67.76%
-52.4 M OPERATING CASH FLOW
-402.19%
-57.1 M INVESTING CASH FLOW
-6669.16%
0 FINANCING CASH FLOW
0.00%
Balance Sheet RAPT Therapeutics, Inc.
image
Current Assets 235 M
Cash & Short-Term Investments 231 M
Receivables 0
Other Current Assets 4.18 M
Non-Current Assets 5.09 M
Long-Term Investments 0
PP&E 4.7 M
Other Non-Current Assets 389 K
96.14 %Total Assets$240.3m
Current Liabilities 48.4 M
Accounts Payable 1.28 M
Short-Term Debt 2.42 M
Other Current Liabilities 44.7 M
Non-Current Liabilities 2.07 M
Long-Term Debt 2.07 M
Other Non-Current Liabilities 1
4.80 %88.56 %4.11 %Total Liabilities$50.4m
EFFICIENCY
Earnings Waterfall RAPT Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 136 M
Operating Income -136 M
Other Expenses -6.24 M
Net Income -130 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)000(136m)(136m)6m(130m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-68.38% ROE
-68.38%
-54.04% ROA
-54.04%
-70.01% ROIC
-70.01%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis RAPT Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -130 M
Depreciation & Amortization 1.2 M
Capital Expenditures -122 K
Stock-Based Compensation 19.9 M
Change in Working Capital 25.9 M
Others 33.9 M
Free Cash Flow -83.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets RAPT Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for RAPT of $20.6 , with forecasts ranging from a low of $2 to a high of $55 .
RAPT Lowest Price Target Wall Street Target
2 USD -82.82%
RAPT Average Price Target Wall Street Target
20.6 USD 76.73%
RAPT Highest Price Target Wall Street Target
55 USD 372.51%
Price
Max Price Target
Min Price Target
Average Price Target
60605050404030302020101000Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership RAPT Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 week ago
Best Momentum Stocks to Buy for July 15th FUTU, IVZ and RAPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2025. zacks.com - 1 week ago
Does Rapt Therapeutics (RAPT) Have the Potential to Rally 183.83% as Wall Street Analysts Expect? The consensus price target hints at an 183.8% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 week ago
New Strong Buy Stocks for July 15th FUTU, PAAS, RAPT, HG and IVZ have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2025. zacks.com - 1 week ago
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its board of directors. Dr. Braunstein was appointed as a member of the Audit Committee of the Board and Dr. Dombkowski was appointed as a member of the Nominating and Corporate Governance Committee of the Board. The company's lead product candidate RPT904, is a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E (“IgE”), a key driver of several allergic diseases. RPT904 is currently completing Phase 2 trials in chronic spontaneous urticaria and asthma, and RAPT plans to initiate a Phase 2 clinical trial for food allergy later this year. globenewswire.com - 1 month ago
Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know The consensus price target hints at a 282.7% upside potential for Rapt Therapeutics (RAPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. globenewswire.com - 1 month ago
RAPT Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in June: globenewswire.com - 1 month ago
Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 months ago
RAPT Therapeutics Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. globenewswire.com - 2 months ago
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D. globenewswire.com - 3 months ago
RAPT Therapeutics to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: globenewswire.com - 4 months ago
8. Profile Summary

RAPT Therapeutics, Inc. RAPT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 192 M
Dividend Yield 0.00%
Description RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Contact 561 Eccles Avenue, South San Francisco, CA, 94080 https://www.rapt.com
IPO Date Oct. 31, 2019
Employees 67
Officers Dr. Brian Russell Wong M.D., Ph.D. Chief Executive Officer, President & Director Dr. William Ho M.D., Ph.D. Chief Medical Officer Dr. Nipun Davar MBA, Ph.D. Senior Vice President of Technical Operations Steve Young Ph.D. Vice President of Technology Mr. Michael Listgarten General Counsel Dr. Paul Kassner Ph.D. Senior Vice President of Biology Ms. Jennifer Nicholson Senior Vice President of Regulatory Affairs & Quality Assurance Ms. Gwen R. Carscadden Chief Human Resources Officer Mr. Rodney K. B. Young Chief Financial Officer, Principal Accounting Officer & Secretary Dr. Dirk G. Brockstedt Ph.D. Chief Scientific Officer